Treatment regimens for chronic hepatitis C virus genotypes 4, 5, and 6 infection in adults
- Andrew J Muir, MD, MHS
Andrew J Muir, MD, MHS
- Chief of Gastroenterology at Duke University
Six major genotypes of the hepatitis C virus (HCV) have been discovered around the world. All HCV genotypes can cause both acute and chronic hepatitis. The acute process is self-limited, rarely causes hepatic failure, and usually leads to chronic infection. Chronic HCV infection often follows a progressive course over many years and can ultimately result in cirrhosis, hepatocellular carcinoma, and the need for liver transplantation. (See "Clinical manifestations and natural history of chronic hepatitis C virus infection".)
The goal of treatment is to eradicate HCV RNA, which is predicted by the achievement of a sustained virologic response (SVR), defined by the absence of HCV RNA by polymerase chain reaction 12 weeks after stopping treatment. An SVR is associated with a 99 percent chance of being HCV RNA negative during long-term follow-up and can therefore be considered cured of the HCV infection . Achievement of an SVR has also been associated with improved clinical outcomes. (See "Overview of the management of chronic hepatitis C virus infection" and "Patient evaluation and selection for antiviral therapy for chronic hepatitis C virus infection", section on 'Rationale for treatment'.)
HCV drug development has predominantly focused on genotypes 1, 2, and 3, which are the most common genotypes in Europe and North America. With the advent of direct-acting antiviral agents with broad coverage against all genotypes, patients with genotypes 4, 5, and 6 also have new treatment options.
This topic will review the antiviral treatment of patients with chronic HCV genotypes 4, 5, and 6 infections. General management of chronic HCV infection, evaluation and selection of patients for antiviral treatment, antiviral treatment of patients with other genotypes, and the treatment of acute HCV infection are discussed elsewhere:
- Swain MG, Lai MY, Shiffman ML, et al. A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin. Gastroenterology 2010; 139:1593.
- Recommendations for Testing, Managing, and Treating Hepatitis C. Joint panel from the American Association of the Study of Liver Diseases and the Infectious Diseases Society of America. http://www.hcvguidelines.org/ (Accessed on August 01, 2016).
- European Association for the Study of the Liver. Electronic address: firstname.lastname@example.org. EASL Recommendations on Treatment of Hepatitis C 2016. J Hepatol 2017; 66:153.
- World Health Organization. Guidelines for the screening, care, adn treatment of persons with hepatitis C infection. April 2014. http://apps.who.int/iris/bitstream/10665/111747/1/9789241548755_eng.pdf?ua=1 (Accessed on April 14, 2014).
- Mohamoud YA, Mumtaz GR, Riome S, et al. The epidemiology of hepatitis C virus in Egypt: a systematic review and data synthesis. BMC Infect Dis 2013; 13:288.
- Abd Elrazek AE, Bilasy SE, Elbanna AE, Elsherif AE. Prior to the oral therapy, what do we know about HCV-4 in Egypt: a randomized survey of prevalence and risks using data mining computed analysis. Medicine (Baltimore) 2014; 93:e204.
- Kamal SM, Nasser IA. Hepatitis C genotype 4: What we know and what we don't yet know. Hepatology 2008; 47:1371.
- Smuts HE, Kannemeyer J. Genotyping of hepatitis C virus in South Africa. J Clin Microbiol 1995; 33:1679.
- Nguyen MH, Keeffe EB. Prevalence and treatment of hepatitis C virus genotypes 4, 5, and 6. Clin Gastroenterol Hepatol 2005; 3:S97.
- Kohli A, Kapoor R, Sims Z, et al. Ledipasvir and sofosbuvir for hepatitis C genotype 4: a proof-of-concept, single-centre, open-label phase 2a cohort study. Lancet Infect Dis 2015; 15:1049.
- Abergel A, Asselah T, Metivier S, et al. Ledipasvir-sofosbuvir in patients with hepatitis C virus genotype 5 infection: an open-label, multicentre, single-arm, phase 2 study. Lancet Infect Dis 2016; 16:459.
- Feld JJ, Jacobson IM, Hézode C, et al. Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection. N Engl J Med 2015; 373:2599.
- Hassanein T, Wyles D, Wang S, et al. SURVEYOR-II, Part 4: Glecaprevir/Pibrentasvir [ABT493+ABT530] Demonstrates High SVR Rates in Patients With HCV Genotype 2, 4, 5, or 6 Infection Without Cirrhosis Following an 8-Week Treatment Duration. Presented at the American Association for the Study of Liver Diseases Liver Meeting, Boston, MA, November 11-15, 2016.
- Forns X, Lee SS, Valdes J, et al. Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial. Lancet Infect Dis 2017.
- Asselah T, Reesink HW, Gerstoft J, et al. High efficacy of grazoprevir and elbasvir with or without ribavirin in 103 treatment-naive and experienced patients with HCV genotype 4 infection: A pooled analysis. Presented at the American Association for the Study of Liver Diseases Liver Meeting, San Francisco CA, November 13-17, 2015. Abstract #251.
- Hézode C, Asselah T, Reddy KR, et al. Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial. Lancet 2015; 385:2502.
- Ruane PJ, Ain D, Stryker R, et al. Sofosbuvir plus ribavirin for the treatment of chronic genotype 4 hepatitis C virus infection in patients of Egyptian ancestry. J Hepatol 2015; 62:1040.
- Moreno C, Hezode C, Marcellin P, Bourgeois S, Francque S, Samuel D, et al. Simeprevir with peginterferon/ribavirin in treatment-naïve or experienced patients with chronic HCV genotype 4 infection: Interim results of a Phase III trial. 14th European AIDS Conference, 2013. Brussels, Belgium.
- Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013; 368:1878.
- http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204671s000lbl.pdf. (Accessed on February 10, 2014).
- Legrand-Abravanel F, Nicot F, Boulestin A, et al. Pegylated interferon and ribavirin therapy for chronic hepatitis C virus genotype 4 infection. J Med Virol 2005; 77:66.
- Derbala M, Amer A, Bener A, et al. Pegylated interferon-alpha 2b-ribavirin combination in Egyptian patients with genotype 4 chronic hepatitis. J Viral Hepat 2005; 12:380.
- D'Heygere F, George C, Van Vlierberghe H, et al. Efficacy of interferon-based antiviral therapy in patients with chronic hepatitis C infected with genotype 5: a meta-analysis of two large prospective clinical trials. J Med Virol 2011; 83:815.
- Gane EJ, Hyland RH, An D, et al. Efficacy of ledipasvir and sofosbuvir, with or without ribavirin, for 12 weeks in patients with HCV genotype 3 or 6 infection. Gastroenterology 2015; 149:1454.
- Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461:399.
- Lam KD, Trinh HN, Do ST, et al. Randomized controlled trial of pegylated interferon-alfa 2a and ribavirin in treatment-naive chronic hepatitis C genotype 6. Hepatology 2010; 52:1573.
- Hézode C, Fontaine H, Dorival C, et al. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890. J Hepatol 2013; 59:434.
- Afdhal NH, Reau N, Everson GT, et al. Safety and efficacy of telaprevir (TVR) or boceprevir (BOC) in patientns with cirrhosis: Interim results of a longitudinal, observational study. Presented at the 64th annual meeting of the American Association for the Study of Liver Diseases, Washington, DC, November 1-5, 2013.
- Manns M, Samuel D, Gane EJ, et al. Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial. Lancet Infect Dis 2016; 16:685.
- Curry MP, O'Leary JG, Bzowej N, et al. Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis. N Engl J Med 2015; 373:2618.
- Bourlière M, Gordon SC, Flamm SL, et al. Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection. N Engl J Med 2017; 376:2134.
- Chung RT, Andersen J, Volberding P, et al. Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 2004; 351:451.
- Carrat F, Bani-Sadr F, Pol S, et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA 2004; 292:2839.
- Sulkowski M, Pol S, Mallolas J, et al. Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial. Lancet Infect Dis 2013; 13:597.
- Sulkowski MS, Sherman KE, Dieterich DT, et al. Combination therapy with telaprevir for chronic hepatitis C virus genotype 1 infection in patients with HIV: a randomized trial. Ann Intern Med 2013; 159:86.
- Dieterich D, Rockstroh JK, Orkin C, et al. Simeprevir (TMC435) with pegylated interferon/ribavirin in patients coinfected with HCV genotype 1 and HIV-1: a phase 3 study. Clin Infect Dis 2014; 59:1579.
- Sulkowski MS, Naggie S, Lalezari J, et al. Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection. JAMA 2014; 312:353.
- EPIDEMIOLOGY OF GENOTYPES 4, 5, AND 6
- DECIDING WHEN TO TREAT
- SELECTION OF TREATMENT REGIMENS
- Genotype 4
- Genotype 5
- Genotype 6
- TREATMENT CONSIDERATIONS IN SPECIFIC POPULATIONS
- Patients with cirrhosis
- - Compensated
- - Decompensated
- Prior failure of direct-acting antiviral regimens
- Recurrence after liver transplantation
- Patients with renal impairment
- HIV-HCV co-infection
- MONITORING DURING INTERFERON-FREE REGIMENS
- ADMINISTRATION OF INTERFERON CONTAINING REGIMENS
- FOLLOW-UP AFTER TREATMENT
- SOCIETY GUIDELINE LINKS
- SUMMARY AND RECOMMENDATIONS